KOD - コディアック・サイエンシズ (Kodiak Sciences Inc) コディアック・サイエンシズ

 KODのチャート


 KODの企業情報

symbol KOD
会社名 Kodiak Sciences Inc (コディアック・サイエンシズ)
分野(sector)   
産業(industry)   
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Kodiak Sciences Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics to treat ophthalmic diseases. The Company’s Antibody Biopolymer Conjugate (ABC) platform focuses on merging the fields of antibody-based and chemistry-based therapies. The Company in addition to its lead product candidate KSI-301 is a molecule for age-related macular degeneration and diabetic retinopathy. The Company has leveraged its ABC platform to build a pipeline of product candidates in various stages of development including KSI-501 a dual inhibitor ABC for the treatment of neovascular retinal diseases such as wet AMD and diabetic retinopathy.   コディアック・サイエンシズは米国のバイオ医薬品企業。羅漢率の高い眼科疾患のための新たな治療薬の開発に従事。主な製品候補には、加齢黄斑変性症および糖尿病性網膜症のための抗血管内皮増殖因子薬KSI-301があるほか、前臨床段階のプロジェクトとして糖尿病黄斑浮腫やぶどう膜炎の治療薬の臨床試験を手掛ける。本社所在地はカリフォルニア州パロアルト。   Kodiak Sciences Inc. is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, Kodiak is focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Its ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, its bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and the company is expanding its early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA.
本社所在地 2631 Hanover Street Palo Alto CA 94304 USA
代表者氏名
代表者役職名
電話番号 +1 650-281-0850
設立年月日 39965
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 28人
url www.kodiak.com
nasdaq_url https://www.nasdaq.com/symbol/kod
adr_tso
EBITDA EBITDA(百万ドル) -23.81400
終値(lastsale) 10.01
時価総額(marketcap) 0
時価総額 時価総額(百万ドル) 343.04880
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 419.03180
当期純利益 当期純利益(百万ドル) -32.48200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Kodiak Sciences Inc revenues was not reported. Net loss increased 39% to $16.3M. Higher net loss reflects Interest Expense increase from $12K to $3.3M (expense) General and administrative increase of 85% to $3M (expense) Stock-based Compensation in SGA increase from $52K to $384K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.33 to -$0.46.

 KODのテクニカル分析


 KODのニュース

   Charles Bray, Chairman, of Eastinco on a "Transformational" JV & John Meyer on Kodal, Empire and Cora - Vox Markets  2021/06/16 12:12:48 VOX Markets
Eastinco Mining and Exploration #EM.P provides a trading update and news on a JV which they describe as transformational. John Meyer talks about: Kodal Minerals, Empire Metals & Cora Gold.
   Small Cap Feast - Itaconix; Kodal Minerals; Oncimmune; Xpediator and more...  2021/06/08 12:54:00 Proactive Investors UK
UK SPAC (formerly Mountfield Group and now an AIM Rule 15 Shell) has applied for admission to the AQSE Growth Market. The Company recently raised £3.1m in a placing, giving the Company flexibility in pursuing a reverse take-over transaction. The Directors of the Company are currently in the process of identifying and assessing reverse takeover opportunities
   Today''s Market View - Empire Metals; Kodal Minerals and more...  2021/06/08 11:10:00 Proactive Investors UK
Empire Metals* (AIM:EEE) Sale of Georgian copper and gold assets for US$3.3m GoldStone Resources* (AIM:GRL) Warrant exercise provides £120k of funding to company Kodal Minerals* (LON:KOD) Bougouni Lithium Project moves s step closer to final approval Lucara Diamonds (TSX:LUC) Karowe mine yields third diamond larger than 300carats in size this year
   Kodal Minerals moves a step closer to getting mining licence for Bougouni lithium project  2021/06/08 08:35:00 Proactive Investors UK
Kodal said it will pay the £135,000 application fee promptly
   What is the significant progress made by Kodal Minerals for the Nielle gold exploration project?  2021/05/28 15:47:15 Kalkine Media
Summary The mining license application for the Bougouni Lithium Project is progressing well despite the political turbulence in Mali. KOD is well prepared for the reverse circulation (RC) drilling programme in the Nielle gold exploration project. The aircore drilling will be completed in two weeks. Kodal Minerals PLC (LON: KOD) is the mining stock listed on the London stock exchange. KODs shares have generated a return of 635.71% in the last 12 months. Company Overview Kodal Minerals PLC is a mining Company focused on Bougouni Lithium Project and gold projects in West Africa. KOD is listed on the FTSE AIM All-Share index. Recent Update on Gold Exploration activities Nielle Project The Company had initiated aircore drilling at the Nielle Project in northern Cote d''Ivoire to test for gold mineralization. Moreover, it is expected that the 5,000 metres of aircore drilling would be completed in two weeks. Furthermore, KOD is also prepared for the reverse circulation (RC) drilling programme and expects two weeks of time to complete the activity.
   Kodal Minerals PLC Placing to Raise GBP3.5 million - Replacement  2021/03/22 07:00:00 ADVFN UK
Kodal Minerals PLC 22 March 2021 The following announcement replaces the announcement released on 19 March 2021 at 2:18 p.m. under RNS…
   Kodal Minerals PLC Oversubscribed Placing to Raise GBP3.5 million  2021/03/19 14:18:00 ADVFN UK
Kodal Minerals PLC 19 March 2021 Certain information contained within this announcement is deemed by the Company to constitute inside…
   MOVERS OF WEDNESDAY 17 MARCH 2021 - Vox Markets  2021/03/17 16:30:33 VOX Markets
See Today's Market Movers Featuring Ferrexpo, B90 Holdings, Kodal Minerals, Biome Technologies and Hammerson
   Kodal Minerals : Final loan conversion and change to TVR | MarketScreener  2021/03/17 07:59:01 MarketScreener
Kodal Minerals plc Final loan conversion and change to total voting rights Kodal Minerals, the mineral exploration and development company, announces that… | March 17, 2021
   Kodal Minerals PLC - Final loan conversion and change to TVR - Vox Markets  2021/03/17 07:00:00 VOX Markets
Kodal Minerals, the mineral exploration and development company, announces that it has received a conversion notice in relation to the final US $200,000 of the US $1.5 million unsecured convertible loan agreement with Riverfort Global Opportunities PCC Limited and YA II PN Ltd, details of which were announced on 15 July 2020.. The Investors have elected to…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 コディアック・サイエンシズ KOD Kodiak Sciences Inc)

 twitter  (公式ツイッターやCEOツイッターなど)